Stay updated on Weekly Tisotumab Vedotin in Platinum-Resistant Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the Weekly Tisotumab Vedotin in Platinum-Resistant Ovarian Cancer Clinical Trial page.

Latest updates to the Weekly Tisotumab Vedotin in Platinum-Resistant Ovarian Cancer Clinical Trial page
- Check5 days agoNo Change Detected
- Check13 days agoChange DetectedAdded an explanatory note that publications are automatically filled in from PubMed and included the revision label 'v3.3.2'; the prior PubMed-related wording and the older revision 'v3.2.0' have been removed.SummaryDifference0.1%

- Check20 days agoChange DetectedRemoved the government funding lapse banner, which did not affect core study data or page functionality. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check34 days agoChange DetectedThe screenshots show only minor layout and formatting adjustments; the core study data (title, NCT03657043, conditions, eligibility criteria, outcomes, and locations) remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check56 days agoChange DetectedAdded a Publications section citing a new PubMed article (new core content and proper nouns) with a full bibliographic reference; no deletions present.SummaryDifference2%

- Check63 days agoChange Detected- Added a government funding lapse notice and operating status guidance, and a new version tag (v3.2.0). - Removed the previous version tag (v3.1.0).SummaryDifference2%

- Check70 days agoChange DetectedThe page now indicates a new release (v3.1.0) and has removed the Ovarian cancer resource under Genetic and Rare Diseases Information Center, as well as the older revision tag (v3.0.2).SummaryDifference0.3%

Stay in the know with updates to Weekly Tisotumab Vedotin in Platinum-Resistant Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Weekly Tisotumab Vedotin in Platinum-Resistant Ovarian Cancer Clinical Trial page.